Zoono Advances Shelf-Life Extension with 94% Surge in Quarterly Cash Receipts

Strong Cash Flow Turnaround Highlights Growing Market Traction

Zoono Group Limited (ASX:ZNO) reported a significant financial turnaround for the quarter ending 30 June 2026, with cash receipts nearly doubling to NZ$975,000, up NZ$472,000 or 94% from the prior quarter. This surge propelled the company to a positive operating cash flow of NZ$55,000, an improvement of NZ$238,000, marking a crucial milestone for the biotech firm focused on antimicrobial shelf-life extension solutions.

UK Market Sees First Material Commercial Orders

The UK has emerged as a key growth market, where Zoono and its strategic partner OSY Group Limited have secured their first substantial commercial orders under an exclusive contract with the country's leading soft fruits packaging company. These initial orders have laid the groundwork for scaling production, with further orders anticipated in the next quarter. Final-stage trials with multiple major UK retailers are underway, setting the stage for broader commercial rollout upon successful completion.

South African Operations Establish Recurring Sales

In South Africa, Zoono’s exclusive agreement with the leading large-format corrugated packaging producer is gaining momentum, with three quarterly orders already placed, establishing a consistent purchasing pattern. The company is advancing a store-based commercial trial on tomato board punnets with a prominent retailer and is in advanced negotiations for commercial rollout with grape producers and a plastic packaging manufacturer. This steady progress signals potential for expanded market penetration in the region.

Australian Trials and Multi-Format Packaging Strategy

Zoono has initiated trial programs on soft fruits with key suppliers linked to major Australian food retailers, supported by an exclusive agreement with an Australian plastic packaging partner. Parallel discussions with board-based packaging manufacturers for both small and large formats reflect a comprehensive approach to capturing the diverse Australian packaging market. This dual-track strategy underscores the company’s intent to leverage multiple packaging formats to broaden its commercial footprint.

Global Trials and Adjacent Revenue Streams Expanding

Beyond these core markets, Zoono is conducting multiple trials with multinational food producers across Europe and the Americas, exploring further partnerships and commercial opportunities. The company is also capitalising on its technology’s versatility by expanding into adjacent sectors such as cut flowers, applying its antimicrobial solutions to flower sleeves to reduce supply chain wastage. Additionally, synergistic shelf-life applications combining Zoono’s products with other technologies are under evaluation, potentially unlocking new revenue streams.

Shipping Container Treatment Creates New Recurring Sales

Following successful commercial trials in 2025, Zoono’s antimicrobial products are now used in treating shipping containers transporting fresh produce from South Africa and Namibia to international markets. This application represents a novel recurring sales avenue, with expansion into other countries and shipping companies anticipated to contribute to future revenue growth.

Financial Discipline Amid Growth Initiatives

Quarterly expenditure was primarily directed towards staff costs (NZ$105K), product manufacturing (NZ$133K), and administration and corporate overheads (NZ$677K), with smaller allocations to advertising and marketing (NZ$33K) and interest and research and development (NZ$11K). Related party payments of NZ$114,000 were mainly directors’ fees. Despite these outlays, the company maintained a healthy cash balance of NZ$267,000 at quarter-end, with an estimated 4.85 quarters of funding available based on current operating cash flow.